# VTX958 Versus Placebo for the Treatment of Moderate to Severe Psoriasis

> **NCT05655299** · PHASE2 · TERMINATED · sponsor: **Ventyx Biosciences, Inc** · enrollment: 222 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** VTX958 Dose A
- **DRUG:** VTX958 Dose B
- **DRUG:** VTX958 Dose C
- **DRUG:** VTX958 Dose D
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05655299
- **Lead sponsor:** Ventyx Biosciences, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-11-17
- **Primary completion:** 2023-09-25
- **Final completion:** 2023-12-20
- **Target enrollment:** 222 (ACTUAL)
- **Why stopped:** Business Decision
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05655299

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05655299, "VTX958 Versus Placebo for the Treatment of Moderate to Severe Psoriasis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05655299. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*